Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy

International Journal of Infectious Diseases

Volumn 17, Issue 12, 2013, Pages

  Padmapriyadarsini, C ^a   Bhavani, P K ^a   Tang, Alice ^b   Kumar, Hemanth ^a   Ponnuraja, C ^a   Narendran, G ^a   Hannah, Elizabeth ^a   Ramesh, C ^c   Chandrasekar, C ^d   Wanke, Christine ^e   Swaminathan, Soumya ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^b TUFTS MEDICAL CENTER   (United States)

^c Government Rajaji Hospital   (India)

^d Government Hospital of Thoracic Medicine   (India)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti tuberculosis therapy; ART; Hepatic function; HIV TB co infection; Nevirapine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RIFAMPICIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER FUNCTION; LONGITUDINAL STUDY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; SIDE EFFECT; TOXIC HEPATITIS; VIRUS LOAD;

ANTI-TUBERCULOSIS THERAPY; ART; HEPATIC FUNCTION; HIV-TB CO-INFECTION; NEVIRAPINE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HIV INFECTIONS; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; NEVIRAPINE; RIFAMPIN; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD;

EID: 84888436113     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.08.006     Document Type: Article

References (24)

1. World Health Organization. Global tuberculosis control 2010. Geneva: WHO; 2010. Available at: (accessed on May 9, 2011). http://whqlibdoc.who.int/publications/2010/9789241564069_eng.pdf.
2. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendation for a public health approach. Geneva: WHO: 2010. Available at: (accessed on September 9, 2010). http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.
3. Abdool Karim S.S., Naidoo K., Grobler A., Padayatchi N., Baxter C., Gray A., et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362:697-706.
4. Khan F.A., Minion J., Pai M., Royce S., Burman W., Harries A.D., et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010, 50:1288-1299.
5. World Health Organization. Treatment of tuberculosis. 4th ed. Geneva: WHO; 2010. Available at: (accessed September 9, 2010). http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf.
6. Manosuthi W., Sungkarnuparph S., Thakkinstian A., Vibhagool A., Kiertiburanakul S., Rattanasiri S., et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005, 19:1481-1486.
7. Friedland G., Khoos S., Jack C., Lalloo U. Administration of efavirenz (600mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006, 58:1299-1302.
8. Shipton L.K., Wester C.W., Stock S., Ndwapi N., Gaolathe T., Thior I., et al. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV coinfection in Botswana. Int J Tuberc Lung Dis 2009, 13:360-366.
9. Parthasarathy R., Sarma G.R., Janardhanam B., Ramachandran P., Shantha T., Sivasubramanian S., et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986, 67:99-108.
10. Padmapriyadarsini C., Ramesh Kumar S., Terrin N., Narendran G., Menon P.A., Ramachandran G., et al. Dyslipidemia among HIV infected patients with tuberculosis taking once-daily nonnucleoside reverse transcriptase inhibitor based antiretroviral therapy in India. Clin Infect Dis 2011, 52:540-546.
11. DAIDS Table for grading the severity of adult and pediatric adverse events. Bethesda, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases; 2004. Available at: (accessed on 23rd July 2013). http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf.
12. Weidle P.J., Moore D., Mermin J., Buchacz K., Were W., Downing R., et al. Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda. AIDS Patient Care STDS 2008, 22:787-795.
13. Moses M., Zachariah R., Tayler-Smith K., Misinde D., Foncha C., Manzi M., et al. Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi. Int J Tuberc Lung Dis 2010, 14:197-202.
14. Olivia J., Moreno S., Sanz J., Ribera E., Molina J.A., Rubio R., et al. Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. AIDS 2003, 17:637-638.
15. Swaminathan S., Padmapriyadarsini C., Venkatean P., Narendran G., Ramesh Kumar S., Iliayas S., et al. Efficacy and safety of once-daily nevirapine or efavirenz based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis 2011, 53:716-724.
16. Manfredi R., Calza L., Chicod F. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine. HIV Clin Trials 2005, 6:302-311.
17. Kim A.A., Wanjiku L., Macharia D.K., Wangai M., Isavwa A., Abdi H., et al. Adverse events in HIV-infected persons receiving antiretroviral drug regimens in a large urban slum in Nairobi, Kenya, 2003-2005. J Int Assoc Physician AIDS Care (Chic.) 2007, 6:206-209.
18. Patel A., Patel K., Patel J., Shah N., Patel B., Rani S. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral naïve patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr 2004, 37:1166-1169.
19. Manosuthi W., Mankatitham W., Lueangniyomkul A., Chimsuntorn S., Sungkanuparph S. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med 2008, 9:294-299.
20. Pedral-Sampaio D.B., Alves C.R., Netto E.M., Brites C., Oliveira A.S., Badaro R. Efficacy and safety of efavirenz in HIV patients on rifampin for tuberculosis. Braz J Infect Dis 2004, 8:211-216.
21. Towner W.J., Xu L., Leyden W.A., Horberg M.A., Chao C.R., Tang B., et al. The effect of HIV infection, immunodeficiency and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr 2012, 60:321-327.
22. Stern J.O., Robinson P.A., Love J., Lanes S., Imperiale M.S., Mayers D.L. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003, 34(Suppl 1):s21-s33.
23. Padmapriyadarsini C., Chandrabose J., Victor L., Hanna L.E., Arunkumar N., Swaminathan S. Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function. J Postgrad Med 2006, 52:92-96.
24. Saravanan S., Velu V., Kumarasamy N., Nandakumar S., Murugavel K.G., Balakrishnan P., et al. Coinfection of hepatitis B and hepatitis C virus in HIV-infected patients in south India. World J Gastroenterol 2007, 13:5015-5020.